Baidu
map

Neurology:降压药或可降低阿尔茨海默病发病风险

2013-08-20 geniusgodyu dxy

认知功能正常或轻微认知功能障碍(MCI)患者,使用利尿剂、血管紧张素1受体阻滞剂(ARB)、血管紧张素转化酶抑制剂(ACEI)、钙通道阻滞剂(CCB)或β受体阻滞剂(BB)是否与阿尔茨海默病(AD)痴呆风险下降相关尚不清楚。为此,美国约翰斯霍普金斯大学SevilYasar等人进行了一项研究,研究结果在线发表在2013年8月2日的Neurology杂志上。研究结果提示:利尿剂、ARB和ACEI的应用

认知功能正常或轻微认知功能障碍(MCI)患者,使用利尿剂、血管紧张素1受体阻滞剂(ARB)、血管紧张素转化酶抑制剂(ACEI)、钙通道阻滞剂(CCB)或β受体阻滞剂(BB)是否与阿尔茨海默病(AD)痴呆风险下降相关尚不清楚。为此,美国约翰斯霍普金斯大学SevilYasar等人进行了一项研究,研究结果在线发表在2013年8月2日的Neurology杂志上。【原文下载

研究结果提示:利尿剂、ARB和ACEI的应用与认知功能正常志愿者AD痴呆风险下降相关。然而,MCI患者中,只有利尿剂与志愿者的AD痴呆风险下降相关。



入选研究对象年龄至少75岁、认知正常(1928位)或MCI(320位),平均随访6.1年。校正混杂因素后使用Cox构成比风险模型。

研究结果显示:15.6%的志愿者使用利尿药、6.1%使用ARB、15.1%使用ACEI、14.8%使用CCB及20.5%使用BB。2248位志愿者中,290位(占13%)最后出现了AD痴呆。认知功能正常志愿者中,各种降压药使用者出现新发AD痴呆风险比分别为:利尿剂0.51;ARB0.31;ACEI0.50;CCB0.62,BB0.58。在平均收缩压高于140mmHg的情况下,以上数据没有发现显著改变。MCI志愿者中,只有使用利尿剂与卒中风险降低相关。

原始出处:

Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, Fitzpatrick AL, Fried LP, Kawas CH, Sink KM, Williamson JD, Dekosky ST, Carlson MC; For the Ginkgo Evaluation of Memory (GEM) Study Investigators.Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study.Neurology. 2013 Aug 2.  【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816586, encodeId=7fef1816586b1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Jun 13 08:17:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999331, encodeId=86c119993319c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 14 20:17:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817609, encodeId=579c181e609cb, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Sep 07 11:17:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291798, encodeId=1e171291e98a9, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469963, encodeId=e76714699638f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816586, encodeId=7fef1816586b1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Jun 13 08:17:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999331, encodeId=86c119993319c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 14 20:17:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817609, encodeId=579c181e609cb, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Sep 07 11:17:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291798, encodeId=1e171291e98a9, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469963, encodeId=e76714699638f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=)]
    2014-05-14 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816586, encodeId=7fef1816586b1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Jun 13 08:17:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999331, encodeId=86c119993319c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 14 20:17:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817609, encodeId=579c181e609cb, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Sep 07 11:17:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291798, encodeId=1e171291e98a9, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469963, encodeId=e76714699638f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1816586, encodeId=7fef1816586b1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Jun 13 08:17:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999331, encodeId=86c119993319c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 14 20:17:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817609, encodeId=579c181e609cb, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Sep 07 11:17:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291798, encodeId=1e171291e98a9, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469963, encodeId=e76714699638f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1816586, encodeId=7fef1816586b1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri Jun 13 08:17:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999331, encodeId=86c119993319c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 14 20:17:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817609, encodeId=579c181e609cb, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Sep 07 11:17:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291798, encodeId=1e171291e98a9, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469963, encodeId=e76714699638f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 22 08:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=)]

相关资讯

Nature:阿尔茨海默氏症新病因解读

  由美国麻省大学医学院、波恩大学和德国先进欧洲学习与研究中心的研究人员组成的一个国际研究小组,在新研究中证实一个众所周知的免疫炎症过程在阿尔茨海默氏症的病理学中发挥了重要的作用。这一过程导致生成了成熟的促炎性细胞因子白细胞介素1β(IL-1B),与机体抵御感染相关,因此被确立为类风湿性关节炎的一个临床靶点。这一发表在《自然》(Nature)杂志上的研究发现指出了破坏IL-1B生成的药物,例如类风

Eur Heart J:胆碱酯酶抑制剂或降阿尔茨海默型痴呆患者的心梗危险

  瑞典一项研究表明,胆碱酯酶抑制剂(ChEI)与阿尔茨海默型痴呆患者的心肌梗死和死亡危险降低相关,这种相关性随着ChEI剂量的增加而增强。相关论文6月4日在线发表于《欧州心脏杂志》(Eur Heart J)。   该队列研究入选了7073例平均年龄在79岁的阿尔茨海默型痴呆或伴有痴呆的阿尔茨海默病患者。结果在平均随访的503天期间,831例受试者发生看MI或死亡。校正混杂因

MedPage:阿尔茨海默病药物静脉注射免疫球蛋白后期临床试验失败

静脉注射免疫球蛋白(IVIG)在备受关注的III期临床试验中未能阻止阿尔茨海默病的进展,又一个比较有前景的阿尔茨海默病药物的研发似乎要半途而废。根据临床试验主办单位百特国际提供的信息,在名为GAP(Gammaglobulin Alzheimer's Partnership)的安慰剂对照、周期为18个月的临床试验中,接受静脉注射免疫球蛋白治疗的受试者其认知或功能下降比率均没有明显差异,而这两项指标是

阿尔茨海默病治疗指南解析

阿尔茨海默病(Alzheimer's Disease,AD)的发病机制十分复杂,半个世纪以来,随着AD临床和病理研究的深入以及其诊断标准的不断完善,国际上针对其治疗的研究也越来越多,但迄今AD的治疗仍是难点。解析国际上在大量临床研究基础上所做出的新近治疗指南,对目前更好地治疗痴呆,并让患者最大程度获益有着重要的指导作用。国际新近AD治疗指南国际上新近的较权威指南有:2010年由欧洲神经病学联盟(E

Lancet Neurol:阿尔茨海默病征兆早于症状数十年

  研究人员发现,那些具有早发型阿尔茨海默病遗传倾向的年轻成年人,出现脑部异常改变的时间可比记忆、认知障碍症状的出现以及脑部Aβ蛋白沉积早20年以上。这一研究结果在线发表于11月6日Lancet Neurology的两篇文章。美国Banner阿尔茨海默病研究所的主任Eric M. Reiman博士说,这些发现“所引发的问题是对于具有遗传倾向的AD患者来说,其最早的脑部变化是什么,以及我们将来怎样对

Baidu
map
Baidu
map
Baidu
map